Orthopaedicsregenerative medicine

Advanced solutions.
For better movement.

Remedica provides healthcare institutions and private clinics with carefully selected medical devices, professional product presentations and reliable support.

2014Remedica established
4specialised product programmes
B2Bsupport for healthcare professionals
HA injectionsPRP systemsViscoPhi TrioEXOMASSupporting instruments

Remedica programme

Solutions that support
professional decisions.

Four clearly defined product programmes for healthcare institutions, private clinics and specialist practices, supported by personal professional guidance.

01 / HA INJECTIONS
HyaRelief Cross 90 mg

BIOSANBIO

HyaRelief™

A pre-filled syringe with highly purified sodium hyaluronate for intra-articular use and viscoelastic supplementation of synovial fluid.

Product details
02 / COMBINATION FORMULA
ViscoPhi Trio, odprto pakiranje in prednapolnjena brizga

PHIBIO GMBH

ViscoPhi Trio

A combined intra-articular solution with sodium hyaluronate, N-acetylglucosamine and chondroitin sulphate.

Product details
03 / AUTOLOGOUS PROGRAMME
EXOMAS Standard Pack

D-MED

EXOMAS

Standard pack for preparing an autologous plasma fraction rich in extracellular vesicles from the patient's own blood.

Programme details
04 / PRP SYSTEMS
D-MED PRP Kit

D-MED

PRP systems

Complete solutions for the standardised preparation of platelet-rich plasma for professional clinical use.

Explore the programme

How we work

From a professional question
to reliable support.

01

Consultation and selection

We first learn about the field of work, clinical setting and the needs of the professional team.

02

Professional presentation

Medically qualified staff present the product, documentation and correct workflow.

03

Supply and support

We provide reliable supply and remain available for further professional questions.

D—MED / 01

Regenerative medicine

Precision at
every step.

D-MED combines T-LAB's development and professional heritage with solutions for preparing PRP and autologous extracellular vesicles. The programme is designed for healthcare professionals who value a controlled process, consistency and practical use.

Enquire about D-MED
01D-MED PRP KitPRP preparation kit
02D-MED PRP TubesTubes for single centrifugation
03D-MED PRP SyringeDedicated PRP preparation syringe
04EXOMAS Standard PackStandard pack for preparing plasma rich in extracellular vesicles
05NXT S-106Centrifuge for regenerative protocols

D-MED · PRP programme

Products and
technical specifications.

A programme for professional PRP preparation, from blood collection and centrifugation to the final sample. Contact the Remedica team for detailed protocols and configuration selection.

D-MED PRP Kit and packaging

D-MED · CE CLASS IIb

PRP Kit

A complete kit with mutually compatible components for standardised PRP preparation in a closed system. The protocol requires one centrifugation.

Platelet recovery*
89,1 %
Platelet dose*
4.3 billion
Purity*
95,4 %
Enquire
D-MED PRP Tubes packaging

D-MED · CE CLASS IIb

PRP Tubes

The micro-polished inner surface reduces platelet adhesion and mechanical loss during processing. Closed system and single centrifugation.

Pure PRPAmber PRPsingle centrifugation
D-MED PRP Syringe packaging

D-MED · 10 ml

PRP Syringe

A dedicated 10 ml syringe that converts into a centrifuge tube after blood collection and then back into a syringe in two steps.

I-PRFA-PRFCE class IIb

* Results from D-MED development laboratory analyses as stated by the manufacturer. Final results depend on the protocol and sample.

D-MED · autologous programme

EXOMAS
Standard Pack.

EXOMAS Standard Pack is a standard pack for preparing an autologous plasma fraction rich in extracellular vesicles from the patient's own blood. The protocol combines PRP preparation, controlled mechanical processing with the Cellitium 600 μm processor and separation in new-generation PRX tubes.

01PRP preparationpreparation from autologous blood
02Mechanical processingCellitium 600 μm
03Separationnew-generation PRX tubes
4 × PRP tube2 × PRX tubeCellitium 600 μmstandard processing accessories

For trained physicians only. The procedure, patient selection, indications and application must comply with current instructions for use and professional and regulatory requirements.

Professional programme presentation
D-MED EXOMAS Standard Pack
EXOMAS STANDARD PACKAutologous preparation

D-MED · supporting instrument

NXT S-106
Centrifuge.

The centrifuge is a supporting instrument for regenerative protocols and is not a standalone Remedica sales programme. It is presented last as additional equipment for professional use.

Maximum speed
4.000 RPM / 2.270 G
Rotor
6 × 10 ml
Programmes
99 settings
Weight
8 kg
D-MED NXT S-106 centrifuge

Selected scientific publications

Six studies for
professional review.

The selection prioritises recent clinical, comparative and randomised research and also includes clearly identified preclinical work. The summaries do not constitute treatment recommendations.

2026Preclinical · animal modeln = 28

Comparison of Exomine, T‑LAB PRP and Arthrex ACP

A skeletal-muscle injury model in 28 rabbits directly compared Exomine®, T‑LAB PRP®, Arthrex ACP® and a control group. T‑LAB and Arthrex achieved comparable, approximately 2.5- to 3-fold platelet enrichment with no statistically significant difference. Exomine showed a more favourable histological profile of inflammation and scarring, but the results are preclinical and require clinical confirmation.

Acta Orthopaedica Belgica · DOI
2024Randomised controlledn = 84

PRP, exercise or combination therapy for knee osteoarthritis

Three groups compared PRP, supervised exercise and their combination in mild to moderate knee osteoarthritis. The registered randomised study monitored pain and function.

Clinical Orthopaedics and Related Research · DOI
2023Diagnostic · level IVn = 62

Factors influencing PRP properties

In 62 patients with knee osteoarthritis, preparation with the T‑LAB system achieved a dose of 3.25 billion platelets, 77% recovery and 98.4% PRP purity (DEPA classification B-B-A). The study also analysed the influence of baseline platelet count and individual factors.

Acta Orthopaedica et Traumatologica Turcica · DOI
2025Retrospective cohort150 patients · 205 knees

PRP, HA, corticosteroids and NSAIDs in knee osteoarthritis

The cohort study compared pain and function after four approaches in grade 2–3 osteoarthritis. The authors emphasise the retrospective design and individual clinical judgement.

Medicine · DOI
2019Comparative clinicaln = 40

PRP or cortisone for rotator cuff tendon pathology

In 40 patients with chronic shoulder pain, ultrasound-guided PRP and cortisone injections were compared. Both groups improved in pain and function at one and two months; pain reduction at two months was greater in the PRP group.

Turkish Journal of Osteoporosis · DOI

Full texts are held in Remedica's professional archive. External links lead to publisher records or directly to DOI addresses; access may depend on the publisher's policy.

BiosanBio · HA injections

Supporting natural
joint movement.

HyaRelief™ is a line of medical devices for intra-articular use in symptoms of osteoarthritis. The standard line comprises seven variants from 20 to 90 mg, with concentrations from 1.0 to 3.0% and volumes from 2 to 3 ml. It is intended for viscoelastic supplementation or replacement of synovial fluid in the joint.

Standard line7 variants
HyaRelief Cross3 variants
PackagingPre-filled syringe
Clinical data · 20266-month follow-up of HyaRelief™ 2.0%

An open-label phase IV study followed 90 patients with grade III knee osteoarthritis after one application. VAS and WOMAC outcomes improved significantly from baseline at all follow-up points; adverse events in 5.6% of participants were mild and transient. The study had no control group.

Open publication
  • Sterile pre-filled syringe
  • Highly purified sodium hyaluronate
  • For use by trained healthcare professionals
Enquire about HyaRelief

HyaRelief · standard line

The right strength for
professional decisions.

The standard line contains high-quality hyaluronic acid in seven concentration and volume combinations. Product selection and administration regimen are determined by the physician based on clinical judgement.

HyaRelief 1,0 %, 20 mg v 2 ml
20 mg1,0 % · 2 ml
HyaRelief 1,5 %, 30 mg v 2 ml
30 mg1,5 % · 2 ml
HyaRelief 2,0 %, 40 mg v 2 ml
40 mg2,0 % · 2 ml
HyaRelief 2,4 %, 48 mg v 2 ml
48 mg2,4 % · 2 ml
HyaRelief 2,4 %, 60 mg v 2,5 ml
60 mg2,4 % · 2,5 ml
HyaRelief 2,5 %, 75 mg v 3 ml
75 mg2,5 % · 3 ml
HyaRelief 3,0 %, 90 mg v 3 ml
90 mg3,0 % · 3 ml

Cross-linked HA

HyaRelief™ Cross

Highly purified bacterial-origin hyaluronic acid with a cross-linked structure. The manufacturer states one application per treatment cycle and an effect lasting up to 12 months.

HyaRelief Cross 2,4 %, 60 mg v 2,5 ml
Cross 602,4 % · 60 mg · 2,5 ml
HyaRelief Cross 2,5 %, 75 mg v 3 ml
Cross 752,5 % · 75 mg · 3 ml
HyaRelief Cross 3,0 %, 90 mg v 3 ml
Cross 903,0 % · 90 mg · 3 ml

Data and images are taken from the current BiosanBio manufacturer catalogues. The products are intended for use by appropriately trained healthcare professionals.

ViscoPhi Trio – odprto pakiranje in prednapolnjena brizgaPHIBIO · FRANKFURT

PhiBio GmbH · combination formula

ViscoPhi
Trio

A sterile viscoelastic gel for intra-articular use combines three ingredients in one pre-filled syringe: sodium hyaluronate, N-acetylglucosamine and chondroitin sulphate. ViscoPhi Trio complements the Remedica range as a standalone combination solution.

Sodium hyaluronate

Contributes to the viscosity and elasticity of joint fluid, thereby supporting joint lubrication, load cushioning and easier movement.

N-acetylglucosamine

A biological building block of glycosaminoglycans, molecules involved in cartilage matrix structure. Its role in the formula is supportive and does not imply proven cartilage regeneration.

Chondroitin sulphate

Naturally present in cartilage tissue; its negatively charged chains bind water and contribute to cartilage flexibility and resistance to compression.

VariantTrio 60 mg
VariantTrio 90 mg
Available variants
60 mg and 90 mg
Classification
Class III medical device
Use
Intra-articular · single use
Enquire about ViscoPhi Trio

The product is intended for use by appropriately trained healthcare professionals. Data are taken from the manufacturer's documentation and the medical device register.

Company

2014—present

A reliable partner to
healthcare professionals.

Remedica is a Slovenian company established in 2014. We distribute selected medical devices for orthopaedics, regenerative medicine and other specialist fields.

We supply products to healthcare institutions, private clinics and specialist practices. We provide our partners with professional guidance, product presentations by medically qualified staff and support tailored to the needs of their professional team.

ExpertiseReliabilityPersonal approach

Get in touch

For a product. For a presentation.
For professional advice.

Tell us what you need. Together, we will find the right solution for your institution or practice.

Send an enquiry
Remedica d.o.o.Planinska cesta 37A, 6210 Sežanajure@remedica.siVAT ID: SI72308818

Information for healthcare professionals. The products presented on this website are medical devices intended for use by appropriately trained healthcare professionals. The content is not intended for self-diagnosis or self-treatment.